Skip to main content
. 2019 Mar 8;71(4):599–611. doi: 10.1002/art.40753

Figure 2.

Figure 2

Proportion of patients achieving A, 40% improvement in disease activity according to the Assessment of SpondyloArthritis international Society criteria (ASAS40) or B, ASAS20 responses through week 16 when treated with placebo (PBO), ixekizumab every 2 weeks (IXEQ2W), or ixekizumab every 4 weeks (IXEQ4W). * = P < 0.05; † = P < 0.01; ‡ = P < 0.001, all versus placebo by logistic regression analysis, except for week 1 with ASAS40, for which Fisher's exact test was used due to model nonconvergence. Only analyses at week 16 were included in the prespecified multiple testing strategy. n = number of patients in the analysis category; N = number of patients in the analysis population.